UA78103C2 - Use of pharmaceutical composition containing flurenizid for treating pyo-inflammatory processes in oral cavity - Google Patents

Abstract

The invention relates to the pharmaceutical composition used for the prevention and the treatment of the pyo-inflammatory processes in the oral cavity. The composition contains the following ingredients: Flurenizid 1.0 mass parts, Dimexid 49.0 mass parts, ethanol 96% to 100 mass parts.

Description

Description of the invention

The invention belongs to the field of medicine, namely to surgical stomatology, and relates to a new method 2 of prevention and treatment of infectious-inflammatory postoperative complications and purulent-inflammatory diseases of the maxillofacial area.

The problem of prevention and treatment of infectious-inflammatory postoperative complications, purulent-inflammatory diseases of the maxillofacial area worries scientists and practicing doctors.

Successful prevention and treatment depend on the effectiveness of antiseptics. In recent decades, the resistance of many strains of microflora to antibiotics and some antiseptics (furacilin, ectericide, potassium permanganate) has been discovered. The biology and morphology of pathogens have been thoroughly studied, specific diagnostic methods have been developed, and prevention and treatment schemes have been improved. However, the incidence continues to rise. The search for new antiseptic agents and their effective combinations is still relevant.

It is known that one of the most effective drugs for the treatment of purulent wounds is dimexide. Considerable experience of its 72 applications in various fields of medicine. Proven high antimicrobial, local anesthetic, anti-inflammatory, antifungal effect, ability to activate and potentiate the effects of drug substances.

In modern dental practice, Ukrainian-made "Dimexide" is most often used in combination with well-known antiseptic, antibacterial, analgesic, anti-inflammatory, anesthetic agents with the aim of expanding the spectrum of action on the resistant microflora of the oral cavity, achieving the best clinical effect with minimal side reactions, i.e. creating pathogenetically justified schemes rational treatment.

In Ukraine, for the first time, the drug flurenizide was created and introduced into production and medical practice (Register of Industry Innovations 173/15/01. "Flurenizid - a new original Ukrainian anti-tuberculosis and antimicrobial drug / V.M. Boris et al.; Register of Industry Innovations 166/ 02/17, p

The method of using flurenizide in the prevention of purulent-inflammatory complications of caesarean section in women in labor, (9 who were exposed to long-term exposure to small doses of radiation / S.V. Khmil, T.V. Kravets; Register of industry innovations 90/20/04. Method of treatment of complications after removal of malignant neoplasms of the skin / L.I.Petrukh et al.)

Antiseptic agent in the form of 196 solution "Flupetsal" (the composition contains 0.5-1.0 g of flurenizide, 40.0-49.0 g of dimexide 10095 and 59.5-50.0 g of ethyl alcohol 9695) is a transparent liquid of yellow-lemon color o with the smell of alcohol (the smell of dimexide is not felt, which is a great advantage of the drug). Thanks to the combination of (63 antimicrobial and penetrating properties of the ingredients, "Flupetsal" provides a high disinfecting effect, prevents the development of the inflammatory process in the tissues and its transition into the purulent-necrotic phase. Petrukh L.I., Saldan Y.R., Saldan p

V.Y., Gerashchenko II, Mykhalyk O.I.1. 3. The task of this invention is a method of prevention and treatment of infectious-inflammatory postoperative complications, purulent-inflammatory diseases of the maxillofacial area (alveolitis, periodontitis, periostitis), which consists in the use of a new antiseptic agent "Flupetsal" for the treatment of lesions and wounds or applications.

For the first time, we used "Flupetsal" in dental practice for the prevention and treatment of patients with purulent-inflammatory diseases of the maxillofacial area, achieved the desired clinical effect and reduced possible relapses and side reactions in patients to a minimum. 20 dental patients were examined, including 5 patients with postoperative local

I" with complications and alveolitis, 5 - with acute periodontitis, 7 - with chronic periodontitis, Z - with periostitis.

Control group patients received standard general treatment with antimicrobial, anti-inflammatory agents. Local wounds were treated only with furacilin solution (1:5000). and Before the start of treatment, microbiologically different pathogens were determined in all patients (golden and

Ge | epidermal staphylococcus, Escherichia coli, Proteus, Pseudomonas aeruginosa, Klebsiella, Candida and microbial associations). - After treatment, pathogenic microorganisms were not cultured in patients. aw! 20 Example 1. Patient H.M.Y., 45 years old. She turned to the dental department of the Ternopil Regional Clinical Hospital with complaints of aching pain in the maxillofacial area, bad breath, high temperature, general malaise.

During the examination: there is inflammation, redness and swelling of the gums in the area of the socket of the removed tooth. Traces of blood clots with a grayish-white serous-necrotic coating and an unpleasant smell. 29 Clinical diagnosis: acute purulent alveolitis of the lower jaw on the right (second premolar).

GF) Complex treatment is prescribed: analgesia, scraping (curettage) of the hole from the remains of decomposed thrombus and filling it with a fresh blood clot. At the end of the procedure, the area of the gums and the edges of the hole are treated with 190% Flupetsal solution. By 2 hours, the pain subsides.

In the future, 195 ml of "Flupetsal" solution is prescribed to treat the socket of the extracted tooth three times a day for 60 days. Oral analgesics are recommended (if necessary).

The next day, there are obvious signs of epithelization of local tissues in the area of the removed tooth. The general condition of the patient is satisfactory.

After 3 days of treatment with 195 "Flupetsal" solution, a clinical effect and signs of recovery were obtained.

Example 2. Patient K.G.I., 28 years old. He turned to the dental department of the Ternopil Branch Clinical Hospital with complaints of pain in the area of the causative tooth when biting, eating hot food. Earlier, the patient was injured as a result of a blow.

During examination: tenderness during palpation. Percussion of an intact maxillary central incisor on the right causes sharp pain.

Clinical diagnosis: acute serous periodontitis of the upper jaw on the right (central incisor).

Anesthesia of the upper jaw on the right, trepanation of the crown of the tooth are performed. At the end of the manipulations, the mucous membrane around the central incisor is treated with 195 Flupetsal solution for disinfection.

In the future, 195 ml of "Flupetsal" solution is prescribed three times a day for a 10-day period of conservative treatment.

For the prevention and preservation of the tooth, 195 "Flupetsal" solution is recommended periodically for gum treatment and 7/0 Oral hygiene.

Example 3. Patient P.V.G., 54 years old. He turned to the stomatological department of the Ternopil Regional Clinical Hospital with complaints of acute throbbing pain in the area of the causative tooth and irradiation in the hip, ear, lower and upper jaw on the left, elevated body temperature.

During external examination: asymmetry of the face, sharp pain during palpation, enlargement of submandibular 7/5 lymph nodes on the left. Examination of the oral cavity: convulsive compression of the jaws (trismus of the 1st degree), swelling, infiltration, hyperemia and smoothing along the transitional fold at the site of the lesion, fluctuation, the crown part of the first molar is completely destroyed, a white plaque on the tongue.

Clinical diagnosis: acute purulent periostitis of the lower jaw on the left (first molar).

Anesthesia of the lower jaw on the left, surgical dissection of the periosteum, tooth extraction and cleaning are performed. 2. The patient is offered to rinse his mouth with furacilin solution (1:5000). First, the wound is flushed with furatsilin, then 0.5 ml of 195 ml of "Flupetsal" solution is injected and drained. Manipulations are repeated every other day for a week at an appointment with a dentist-surgeon.

At the same time, the patient is prescribed to rinse the mouth every 2 hours with a furatsilin solution (1:5000), followed by treatment of the mucous membrane around the wound with 195 Flupetsal solution. Recommended with 2g5 Use oral pathogenetic agents.

The patient carries out the doctor's appointment within 10 days to prevent complications. at);

Data on the results of treatment of 20 patients with purulent-inflammatory diseases of the maxillofacial area are presented in

Tables 1.

According to the results of clinical data, the new antiseptic agent "Flupetsal" in the form of a 195 solution provides a 100905 clinical effect in case of postoperative local complications, alveolitis and acute periodontitis.

In chronic periodontitis, the clinical effect was achieved in 85.7905. There were only 3 patients with periostitis. The expressed clinical effect was achieved in 66.7905. -

Thus, the method proposed by us for the treatment of patients with purulent-inflammatory diseases of the maxillofacial area using the new domestic antimicrobial drug "Flupetsal" provides a pronounced clinical effect in dentistry. uh-

Table 1

Indicators of the results of the treatment of purulent-inflammatory diseases of the maxillofacial area «

Mo p/p Purulent-inflammatory diseases Control |/Treated with 195 years of Flupetsalu pc Received clinical |95 cured «oo same SHENNY NN 5

Han site // diagnosis of patients 1" alveolitis with chronmnilerodontim 00000005 vv, shchi (ee) In our proposed new composition for the prevention and treatment of purulent-inflammatory diseases from the maxillofacial area, an original combination of ingredients with a wide spectrum of antibiotic, anti-inflammatory, penetrating action is used, which ensures proper hygiene of the oral cavity. (in 50 "Flupetsal" was used for the first time in dental practice, a high clinical effect was achieved and possible relapses and adverse reactions in patients were reduced to a minimum. p" The proposed new composition for the prevention and treatment of purulent-inflammatory diseases of the maxillofacial area will contribute to the successful treatment of patients original antimicrobial agent

Claims (1)

The formula of the invention o The use of a pharmaceutical composition containing components in the following ratio: flurenizide - 1.0 wt.h, dimexide - 49.0 wt.h, ethyl alcohol 96 95 - up to 100 wt.h, for the prevention and treatment of 60 purulent - inflammatory diseases of the oral cavity. Official bulletin "Industrial Property". Book 1 "Inventions, useful models, topographies of integrated microcircuits", 2007, M 2, 15.02.2007. State Department of Intellectual Property of the Ministry of Education and Science of Ukraine. b5